13,523 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund bought 13,523 shares of the life sciences company's stock, valued at approximately $1,073,000.

Other hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new stake in Illumina in the fourth quarter worth about $32,000. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the 4th quarter worth approximately $40,000. Assetmark Inc. grew its holdings in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Illumina in the fourth quarter worth $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina in the fourth quarter valued at $48,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $82.66 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock's 50-day simple moving average is $77.90 and its two-hundred day simple moving average is $104.72. The firm has a market capitalization of $13.09 billion, a P/E ratio of -10.76, a P/E/G ratio of 1.60 and a beta of 1.35. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Illumina's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.98 earnings per share. As a group, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Morgan Stanley lowered their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. TD Cowen cut Illumina from a "buy" rating to a "hold" rating and lowered their price objective for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Canaccord Genuity Group lowered their price target on shares of Illumina from $92.00 to $87.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Finally, Royal Bank of Canada lowered their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $128.84.

Insider Transactions at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.60% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.